Do analysts rate MDRX or OMCL?

Omnicell has a consensus target price of $59.86, suggesting a potential upside of 53.28%. Given Omnicell's stronger consensus rating and higher probable upside, analysts plainly believe Omnicell is more favorable than Veradigm. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Veradigm 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Omnicell 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00

Which has preferable valuation and earnings, MDRX or OMCL?

Omnicell has lower revenue, but higher earnings than Veradigm. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Veradigm $1.53B 0.38 N/A N/A N/A Omnicell $1.18B 1.50 $2.05M $0.44 88.75

Is MDRX or OMCL more profitable?

Omnicell has a net margin of 1.67% compared to Veradigm's net margin of 0.00%. Omnicell's return on equity of 4.00% beat Veradigm's return on equity. Company Net Margins Return on Equity Return on Assets Veradigm N/A N/A N/A Omnicell 1.67% 4.00% 2.46%

Do analysts rate HSTM or MDRX?

HealthStream currently has a consensus price target of $24.00, suggesting a potential downside of 6.40%. Given HealthStream's stronger consensus rating and higher possible upside, equities research analysts clearly believe HealthStream is more favorable than Veradigm. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HealthStream 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Veradigm 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation & earnings, HSTM or MDRX?

HealthStream has higher earnings, but lower revenue than Veradigm. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio HealthStream $304.06M 2.46 $18.34M $0.67 38.27 Veradigm $1.53B 0.38 N/A N/A N/A

Which has higher earnings & valuation, CNGL or MDRX?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Canna-Global Acquisition N/A N/A N/A N/A N/A Veradigm $1.53B 0.38 N/A N/A N/A

Is CNGL or MDRX more profitable?

Company Net Margins Return on Equity Return on Assets Canna-Global Acquisition N/A N/A N/A Veradigm N/A N/A N/A

Do analysts recommend MDRX or FUSE?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Veradigm 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Fusemachines 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, MDRX or FUSE?

Veradigm has higher revenue and earnings than Fusemachines. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Veradigm $1.53B 0.38 N/A N/A N/A Fusemachines $7.71M 4.32 -$930K -$0.03 N/A

Is MDRX or FUSE more profitable?

Company Net Margins Return on Equity Return on Assets Veradigm N/A N/A N/A Fusemachines N/A N/A N/A

Which has preferable earnings & valuation, MDRX or OMQS?

Veradigm has higher revenue and earnings than OMNIQ. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Veradigm $1.53B 0.38 N/A N/A N/A OMNIQ $81.19M 0.02 -$29.43M $0.11 1.17

Is MDRX or OMQS more profitable?

Veradigm has a net margin of 0.00% compared to OMNIQ's net margin of -34.33%. Company Net Margins Return on Equity Return on Assets Veradigm N/A N/A N/A OMNIQ -34.33% N/A -61.97%

Veradigm (MDRX) Competitors

$4.80 0.00 (0.00%)

As of 06/18/2026 03:08 PM Eastern

Compare

MDRX vs. OMCL, HSTM, CNGL, FUSE, and OMQS

Should you buy Veradigm stock or one of its competitors? MarketBeat compares Veradigm with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Veradigm include Omnicell (OMCL), HealthStream (HSTM), Canna-Global Acquisition (CNGL), Fusemachines (FUSE), and OMNIQ (OMQS).

How does Veradigm compare to Omnicell?

Veradigm (NASDAQ:MDRX) and Omnicell (NASDAQ:OMCL) are both small-cap health care technology companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk.

Veradigm has a beta of 0.55, indicating that its share price is 45% less volatile than the broader market. Comparatively, Omnicell has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market.

Omnicell has lower revenue, but higher earnings than Veradigm.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veradigm	$1.53B	0.38	N/A	N/A	N/A
Omnicell	$1.18B	1.50	$2.05M	$0.44	88.75

In the previous week, Veradigm's average media sentiment score of 0.00 equaled Omnicell'saverage media sentiment score.

Company	Overall Sentiment
Veradigm	Neutral
Omnicell	Neutral

Omnicell has a net margin of 1.67% compared to Veradigm's net margin of 0.00%. Omnicell's return on equity of 4.00% beat Veradigm's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veradigm	N/A	N/A	N/A
Omnicell	1.67%	4.00%	2.46%

97.7% of Omnicell shares are held by institutional investors. 2.3% of Veradigm shares are held by insiders. Comparatively, 2.9% of Omnicell shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Omnicell has a consensus target price of $59.86, suggesting a potential upside of 53.28%. Given Omnicell's stronger consensus rating and higher probable upside, analysts plainly believe Omnicell is more favorable than Veradigm.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veradigm	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Omnicell	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00

Summary

Omnicell beats Veradigm on 12 of the 13 factors compared between the two stocks.

How does Veradigm compare to HealthStream?

HealthStream (NASDAQ:HSTM) and Veradigm (NASDAQ:MDRX) are both small-cap health care technology companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, media sentiment, earnings, profitability, analyst recommendations, valuation and risk.

In the previous week, HealthStream had 3 more articles in the media than Veradigm. MarketBeat recorded 3 mentions for HealthStream and 0 mentions for Veradigm. HealthStream's average media sentiment score of 0.37 beat Veradigm's score of 0.00 indicating that HealthStream is being referred to more favorably in the media.

Company	Overall Sentiment
HealthStream	Neutral
Veradigm	Neutral

HealthStream has a net margin of 6.39% compared to Veradigm's net margin of 0.00%. HealthStream's return on equity of 6.47% beat Veradigm's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HealthStream	6.39%	6.47%	4.44%
Veradigm	N/A	N/A	N/A

HealthStream has a beta of 0.47, suggesting that its stock price is 53% less volatile than the broader market. Comparatively, Veradigm has a beta of 0.55, suggesting that its stock price is 45% less volatile than the broader market.

HealthStream has higher earnings, but lower revenue than Veradigm.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HealthStream	$304.06M	2.46	$18.34M	$0.67	38.27
Veradigm	$1.53B	0.38	N/A	N/A	N/A

69.6% of HealthStream shares are owned by institutional investors. 20.4% of HealthStream shares are owned by insiders. Comparatively, 2.3% of Veradigm shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

HealthStream currently has a consensus price target of $24.00, suggesting a potential downside of 6.40%. Given HealthStream's stronger consensus rating and higher possible upside, equities research analysts clearly believe HealthStream is more favorable than Veradigm.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HealthStream	0 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Veradigm	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

HealthStream beats Veradigm on 11 of the 13 factors compared between the two stocks.

How does Veradigm compare to Canna-Global Acquisition?

Canna-Global Acquisition (NASDAQ:CNGL) and Veradigm (NASDAQ:MDRX) are both small-cap business services companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

19.5% of Canna-Global Acquisition shares are owned by institutional investors. 72.1% of Canna-Global Acquisition shares are owned by company insiders. Comparatively, 2.3% of Veradigm shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Canna-Global Acquisition has a beta of -0.06, indicating that its share price is 106% less volatile than the broader market. Comparatively, Veradigm has a beta of 0.55, indicating that its share price is 45% less volatile than the broader market.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Canna-Global Acquisition	N/A	N/A	N/A	N/A	N/A
Veradigm	$1.53B	0.38	N/A	N/A	N/A

In the previous week, Canna-Global Acquisition's average media sentiment score of 0.00 equaled Veradigm'saverage media sentiment score.

Company	Overall Sentiment
Canna-Global Acquisition	Neutral
Veradigm	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Canna-Global Acquisition	N/A	N/A	N/A
Veradigm	N/A	N/A	N/A

Summary

Canna-Global Acquisition and Veradigm tied by winning 2 of the 4 factors compared between the two stocks.

How does Veradigm compare to Fusemachines?

Veradigm (NASDAQ:MDRX) and Fusemachines (NASDAQ:FUSE) are both small-cap computer integrated systems design industry companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, dividends, institutional ownership, media sentiment, risk and profitability.

In the previous week, Fusemachines had 2 more articles in the media than Veradigm. MarketBeat recorded 2 mentions for Fusemachines and 0 mentions for Veradigm. Veradigm's average media sentiment score of 0.00 equaled Fusemachines'average media sentiment score.

Company	Overall Sentiment
Veradigm	Neutral
Fusemachines	Neutral

Veradigm has higher revenue and earnings than Fusemachines.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veradigm	$1.53B	0.38	N/A	N/A	N/A
Fusemachines	$7.71M	4.32	-$930K	-$0.03	N/A

Company	Net Margins	Return on Equity	Return on Assets
Veradigm	N/A	N/A	N/A
Fusemachines	N/A	N/A	N/A

46.8% of Fusemachines shares are owned by institutional investors. 2.3% of Veradigm shares are owned by insiders. Comparatively, 31.8% of Fusemachines shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Veradigm has a beta of 0.55, meaning that its share price is 45% less volatile than the broader market. Comparatively, Fusemachines has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veradigm	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Fusemachines	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Fusemachines beats Veradigm on 6 of the 8 factors compared between the two stocks.

How does Veradigm compare to OMNIQ?

Veradigm (NASDAQ:MDRX) and OMNIQ (NASDAQ:OMQS) are both small-cap computer integrated systems design industry companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, valuation, institutional ownership, earnings, profitability and risk.

5.7% of OMNIQ shares are held by institutional investors. 2.3% of Veradigm shares are held by insiders. Comparatively, 11.6% of OMNIQ shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Veradigm has higher revenue and earnings than OMNIQ.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veradigm	$1.53B	0.38	N/A	N/A	N/A
OMNIQ	$81.19M	0.02	-$29.43M	$0.11	1.17

In the previous week, Veradigm's average media sentiment score of 0.00 equaled OMNIQ'saverage media sentiment score.

Company	Overall Sentiment
Veradigm	Neutral
OMNIQ	Neutral

Veradigm has a net margin of 0.00% compared to OMNIQ's net margin of -34.33%.

Company	Net Margins	Return on Equity	Return on Assets
Veradigm	N/A	N/A	N/A
OMNIQ	-34.33%	N/A	-61.97%

Veradigm has a beta of 0.55, suggesting that its share price is 45% less volatile than the broader market. Comparatively, OMNIQ has a beta of 1.51, suggesting that its share price is 51% more volatile than the broader market.

Summary

Veradigm beats OMNIQ on 5 of the 8 factors compared between the two stocks.

Get Veradigm News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MDRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MDRX vs. The Competition

Export

Metric	Veradigm	Computer integrated systems design Industry	Business Sector	NASDAQ Exchange
Market Cap	$587.04M	$2.73B	$6.75B	$12.60B
Dividend Yield	N/A	3.99%	3.19%	5.81%
P/E Ratio	23.25	2.11	28.87	24.42
Price / Sales	0.38	214.21	377.97	111.09
Price / Cash	N/A	N/A	22.95	37.84
Price / Book	N/A	N/A	5.75	6.60
Net Income	N/A	-$14.66M	$205.44M	$337.10M
7 Day Performance	N/A	3.89%	6.14%	0.83%
1 Month Performance	1.05%	-8.27%	7.37%	2.25%
1 Year Performance	6.67%	-0.58%	35.64%	36.14%

Veradigm Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MDRX Veradigm	N/A	$4.80 flat	N/A	+6.7%	$587.04M	$1.53B	23.25	8,000	Gap Down
OMCL Omnicell	3.0814 of 5 stars	$41.50 -1.1%	$59.86 +44.2%	+39.3%	$1.89B	$1.23B	94.32	3,580
HSTM HealthStream	3.193 of 5 stars	$25.81 +0.6%	$24.00 -7.0%	-3.6%	$754.04M	$311.78M	38.52	1,160	News Coverage
CNGL Canna-Global Acquisition	N/A	$9.00 flat	N/A	N/A	$59.49M	N/A	N/A	2
FUSE Fusemachines	0.4528 of 5 stars	$1.25 +0.7%	N/A	N/A	$36.15M	$7.64M	N/A	317	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MDRX) was last updated on 6/21/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Veradigm (MDRX) Competitors

MDRX vs. OMCL, HSTM, CNGL, FUSE, and OMQS

How does Veradigm compare to Omnicell?

Summary

How does Veradigm compare to HealthStream?

Summary

How does Veradigm compare to Canna-Global Acquisition?

Summary

How does Veradigm compare to Fusemachines?

Summary

How does Veradigm compare to OMNIQ?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDRX vs. The Competition

Veradigm Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Veradigm (MDRX) Competitors

MDRX vs. OMCL, HSTM, CNGL, FUSE, and OMQS

How does Veradigm compare to Omnicell?

Which has more volatility & risk, MDRX or OMCL?

Which has preferable valuation and earnings, MDRX or OMCL?

Does the media refer more to MDRX or OMCL?

Is MDRX or OMCL more profitable?

Do insiders & institutionals have more ownership in MDRX or OMCL?

Do analysts rate MDRX or OMCL?

Summary

How does Veradigm compare to HealthStream?

Does the media favor HSTM or MDRX?

Is HSTM or MDRX more profitable?

Which has more risk and volatility, HSTM or MDRX?

Which has better valuation & earnings, HSTM or MDRX?

Do insiders and institutionals hold more shares of HSTM or MDRX?

Do analysts rate HSTM or MDRX?

Summary

How does Veradigm compare to Canna-Global Acquisition?

Do institutionals and insiders have more ownership in CNGL or MDRX?

Which has more risk & volatility, CNGL or MDRX?

Which has higher earnings & valuation, CNGL or MDRX?

Does the media refer more to CNGL or MDRX?

Is CNGL or MDRX more profitable?

Summary

How does Veradigm compare to Fusemachines?

Does the media favor MDRX or FUSE?

Which has preferable valuation & earnings, MDRX or FUSE?

Is MDRX or FUSE more profitable?

Do insiders & institutionals believe in MDRX or FUSE?

Which has more volatility & risk, MDRX or FUSE?

Do analysts recommend MDRX or FUSE?

Summary

How does Veradigm compare to OMNIQ?

Do institutionals & insiders believe in MDRX or OMQS?

Which has preferable earnings & valuation, MDRX or OMQS?

Does the media refer more to MDRX or OMQS?

Is MDRX or OMQS more profitable?

Which has more risk and volatility, MDRX or OMQS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDRX vs. The Competition

Veradigm Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools